Neopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBc-only cases

dc.contributor.authorSohrabi, Pari
dc.contributor.authorHabip, Zafer
dc.contributor.authorSaribas, Suat
dc.contributor.authorVatan, Asli
dc.contributor.authorDinc, Harika Oyku
dc.contributor.authorAltun, Yagiz M.
dc.contributor.authorKocazeybek, Bekir
dc.date.accessioned2026-02-06T18:26:56Z
dc.date.issued2017
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractAim: Isolated hepatitis B core antibodies (aHBc)-only pattern complicates the diagnosis of HBV infections. We evaluated neopterin and sCD14 levels in HBV infections. Methods: aHBc-only (n: 102), healthy control (healthy control group [HCG], n: 100), and chronic hepatitis (CHB) groups (n: 70) were investigated. Competitive and sandwich ELISA were used. Results: The mean neopterin levels were significantly lower in the aHBc-only group than those in the CHB group (p = 0.0001). No significant difference was found between the aHBc-only group and the HCG (p = 0.854). The mean sCD14 levels were lower in the aHBc-only group than those in the CHB group (p = 0.0001), but no significant difference was found between the aHBc-only group and HCG (p = 0.402). No significant difference was detected between aHBc-only and HCG for mean sCD14 (p = 0.402) and neopterin levels (p = 0.854). Conclusion: These two biomarkers are not useful for diagnosing the aHBc only pattern.
dc.description.sponsorshipInstanbul University Research Fund [45694]
dc.description.sponsorshipThe authors of this study received financial support from Instanbul University Research Fund (grant number 45694). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.identifier.doi10.2217/fvl-2017-0005
dc.identifier.endpage419
dc.identifier.issn1746-0794
dc.identifier.issn1746-0808
dc.identifier.issue8
dc.identifier.orcid0000-0001-9670-2426
dc.identifier.orcid0000-0003-1072-3846
dc.identifier.orcid0000-0002-9624-7790
dc.identifier.orcid0000-0003-3628-7392
dc.identifier.orcid0000-0001-6346-1398
dc.identifier.orcid0000-0002-8833-697X
dc.identifier.orcid0000-0003-0841-6740
dc.identifier.scopus2-s2.0-85028521950
dc.identifier.scopusqualityQ3
dc.identifier.startpage409
dc.identifier.urihttps://doi.org/10.2217/fvl-2017-0005
dc.identifier.urihttps://hdl.handle.net/11129/10704
dc.identifier.volume12
dc.identifier.wosWOS:000408362400005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Virology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260204
dc.subjectHBV
dc.subjectisolated anti-HBc (aHBc-only)
dc.subjectneopterin
dc.subjectsCD14
dc.titleNeopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBc-only cases
dc.typeArticle

Files